Dr. Melanie A. Fisher, MD

Dr. Fisher practices at Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia.

Dr. Fisher's NPI, 1578676227, was assigned on August 16, 2006. Dr. Fisher graduated from Penn State College of Medicine in 1977. Dr. Fisher holds West Virginia license 12292.

Dr. Fisher's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD, at 33 Medical Center Dr, Morgantown, WV 26505.

Dr. Fisher's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia. Dr. Fisher is also affiliated with J.W. Ruby Memorial Hospital. The medical group on file is University Health Associates. Dmand AI also links Dr. Fisher to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fisher practices, 3 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Fisher's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Fisher is board certified in infectious disease by the American Board of Internal Medicine. Dmand AI has Dr. Fisher's licenses on file in 2 states: West Virginia and Pennsylvania.

Dmand AI lists acute skin infection, hiv/aids, lyme disease and pneumonia among the conditions Dr. Fisher treats.

CMS data shows 128 Medicare services from Dr. Fisher across 3 procedure codes in 2024, for 100 Medicare patients. Medicare paid $12,250 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 100 Medicare patients who saw Dr. Fisher in 2024. The largest group is 65 to 74, with 37 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 23% are also on Medicaid. Their average risk score is 2.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fisher's median patient age at 64, with 37% women.

In 2024, Dr. Fisher wrote 304 Medicare Part D claims for 32 patients. 58% of them were for generic drugs. CMS names the drug for 213 of them, across 9 drugs with 11 or more claims each, at $322,837 in total drug cost. In 2023, CMS named 159 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Fisher for performance year 2024, reported through an alternative payment model (APM). Dr. Fisher accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Fisher as offering telehealth.

Dmand AI links 15 papers to Dr. Fisher, published from 2010 to 2024. 2022 was the busiest year, with 3. The most frequent topics are West Virginia, Substance Abuse, Intravenous and Appalachian Region. Dr. Fisher has published most often in PLoS One. Dr. Fisher's most frequent co-authors are Jan E. Palmer, MD, Mark C. Bates, MD and Karen E. Clark, MD.

CMS Open Payments shows 2 general payments to Dr. Fisher from 2 drug and device companies from 2019 to 2021. Education make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $13.

Dr. Fisher graduated from Penn State College of Medicine in 1977.

Dr. Fisher is in network with 21 carriers, including Aetna, Highmark and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.